Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 14/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653663 | 0.89 | HPGD (0.46) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL13917313 | 0.88 | HPGD (0.44) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2660361 | 0.86 | HPGD (0.48) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2653480 | 0.86 | HPGD (0.48) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2659359 | 0.84 | HPGD (0.58) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2654001 | 0.83 | HPGD (0.50) | HPGDENPP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL2653778 | 0.77 | HPGD (0.58) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL2653282 | 0.77 | HPGD (0.46) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL2654063 | 0.77 | HPGD (0.59) | HPGDALDH1A1SMN1; SMN2NPC1GLA | |
| SCHEMBL2650466 | 0.76 | FGFR1 (0.65) | HPGDALDH1A1SMN1; SMN2NPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | US | claimed |
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062304-A1 | Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex | GABRB1, GABRB2, GABRB3 | HPGD 2480/4885ENPP2 2329/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.